Aktienanalyse zu Kura Oncology Inc (KURA)KURAKura Oncology Inc

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kura Oncology Inc is currently not a strong buy due to its high volatility and recent negative performance, despite positive long-term potential. The current price is $9.08, with a 5-day change of -14.34% and a 20-day change of -22.59%. While the CEO's recent $2.35 million stock purchase indicates confidence, the RSI of 12.03 suggests the stock is oversold, indicating a potential rebound but also high risk. The main risk is the significant insider selling, which has increased by 178.01% over the last month, indicating potential lack of confidence from insiders.

5 analysts cover KURA: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.